View Exam | PowerPak

1. FDA-approved panogenotypic DAA regimens for first-line treatment of chronic HCV infection . . .

A. Are not approved for patients with compensated cirrhosis. B. Have lower efficacy in PWID who are on medication-assisted treatment. C. Are the same for HCV monoinfection and HCV in HIV/HCV coinfection. D. Require pretreatment resistance testing irrespective of HCV genotype.

2. A 56-year-old man with hyperlipidemia, obesity (BMI 32), and CKD has positive confirmatory testing for HCV RNA. He would like to start DAA therapy. Which of the following will you include in your advice for this patient?

A. All DAAs are contraindicated for patients on statin drugs. B. The patient will need to undergo liver-fibrosis staging before selection of DAA regimen. C. All DAAs are contraindicated for patients with CKD (eGFR <30 mL/min/1.73 m²). D. The patient will need to lose weight before initiation of DAA therapy.

3. Discussion of harm-reduction measures for prevention of posttreatment HCV reinfection . . .

A. Should be deferred until confirmation of HCV cure at 12 weeks after the end of treatment. B. Is an integral part of pretreatment patient assessment. C. Is irrelevant if the patient has poor DAA-regimen adherence. D. Should include information on lower cure rates associated with HCV retreatment.

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. FDA-approved panogenotypic DAA regimens for first-line treatment of chronic HCV infection . . .

2. A 56-year-old man with hyperlipidemia, obesity (BMI 32), and CKD has positive confirmatory testing for HCV RNA. He would like to start DAA therapy. Which of the following will you include in your advice for this patient?

3. Discussion of harm-reduction measures for prevention of posttreatment HCV reinfection . . .

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. FDA-approved panogenotypic DAA regimens for first-line treatment of chronic HCV infection . . .

2. A 56-year-old man with hyperlipidemia, obesity (BMI 32), and CKD has positive confirmatory testing for HCV RNA. He would like to start DAA therapy. Which of the following will you include in your advice for this patient?

3. Discussion of harm-reduction measures for prevention of posttreatment HCV reinfection . . .

« Return to Activity

Customers who Purchased
this Activity also Purchased